Analyst Price Targets — BEAM
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 2:20 pm | — | RBC Capital | $26.00 | $30.83 | TheFly | Beam Therapeutics price target raised to $26 from $22 at RBC Capital |
| February 20, 2026 11:29 am | — | Canaccord Genuity | $74.00 | $27.88 | TheFly | Beam Therapeutics initiated with a Buy at Canaccord |
| January 21, 2026 12:44 pm | William Pickering | Tudor Pickering | $41.00 | $31.00 | StreetInsider | Beam Therapeutics Inc (BEAM) PT Raised at Bernstein Following Positive Regulatory Update |
| January 20, 2026 11:44 pm | — | Bernstein | $41.00 | $30.97 | TheFly | Beam Therapeutics price target raised to $41 from $37 at Bernstein |
| January 7, 2026 5:40 am | Michael Yee | UBS | $28.00 | $28.34 | StreetInsider | UBS Starts Beam Therapeutics Inc (BEAM) at Neutral |
| November 24, 2025 1:11 pm | — | Evercore ISI | $35.00 | $23.32 | TheFly | Beam Therapeutics initiated with an Outperform at Evercore ISI |
| October 9, 2025 3:43 pm | — | Jefferies | $41.00 | $27.86 | TheFly | Beam Therapeutics initiated with a Buy at Jefferies |
| May 7, 2025 12:18 pm | Debjit Chattopadhyay | Guggenheim | $55.00 | $15.99 | TheFly | Beam Therapeutics price target lowered to $55 from $78 at Guggenheim |
| March 3, 2025 2:37 pm | — | Scotiabank | $25.00 | $25.10 | TheFly | Beam Therapeutics price target raised to $25 from $24 at Scotiabank |
| January 7, 2025 12:50 pm | William Pickering | Tudor Pickering | $37.00 | $27.08 | StreetInsider | Bernstein SocGen Group Upgrades Beam Therapeutics Inc (BEAM) to Outperform |
Latest News for BEAM
Invasive species represent a $5.4 trillion global problem, with U.S. economic impact alone exceeding $500 billion annually. That's according to Ben Lamm, CEO of Colossal Biosciences. On episode 245 of the Moonshots with Peter Diamandis podcast, Lamm made the case that gene drive technology is the only scalable, humane answer. "In New Zealand, in Australia,... Colossal's Ben Lamm Says Invasive Species Is a $5.4…
CEO John Evans sold 30,078 company shares for a transaction value of ~$739,000 on April 1, 2026. The sale represented 2.5% of his direct holdings.
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) insider Amy Simon sold 6,700 shares of the business's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $24.58, for a total transaction of $164,686.00. Following the transaction, the insider directly owned 102,735 shares of the company's stock, valued
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) insider Christine Bellon sold 5,956 shares of Beam Therapeutics stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $24.58, for a total value of $146,398.48. Following the sale, the insider owned 109,711 shares in the company, valued at $2,696,696.38.
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) President Giuseppe Ciaramella sold 11,810 shares of the company's stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $24.58, for a total transaction of $290,289.80. Following the completion of the transaction, the president owned 218,406 shares in
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BEAM.
U.S. House Trading
No House trades found for BEAM.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.